Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | TOP1 | P11387 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302316 | 1.00 | METTL3 (0.46) | METTL3GSK3BCDK2TOP1ADORA1 | |
| SCHEMBL1301276 | 0.92 | METTL3 (0.47) | METTL3GSK3BTP53MAPTSMN1; SMN2 | |
| SCHEMBL1301270 | 0.92 | METTL3 (0.47) | METTL3GSK3BTP53MAPTSMN1; SMN2 | |
| SCHEMBL1301713 | 0.88 | METTL3 (0.49) | METTL3GSK3BKMT2AHDAC6KDM4E | |
| SCHEMBL1301707 | 0.88 | METTL3 (0.49) | METTL3GSK3BKMT2AHDAC6KDM4E | |
| SCHEMBL1300902 | 0.87 | METTL3 (0.42) | METTL3GSK3BTOP1MAPTSMN1; SMN2 | |
| SCHEMBL1300908 | 0.87 | METTL3 (0.42) | METTL3GSK3BTOP1MAPTSMN1; SMN2 | |
| SCHEMBL1300924 | 0.86 | METTL3 (0.46) | METTL3GSK3BTOP1KMT2AKDM4E | |
| SCHEMBL1300920 | 0.86 | METTL3 (0.46) | METTL3GSK3BTOP1KMT2AKDM4E | |
| SCHEMBL1301560 | 0.85 | METTL3 (0.45) | METTL3GSK3BKDM4EALDH1A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885GSK3B 524/4885CDK2 103/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885GSK3B 524/4885CDK2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.